Develop and validate a set of quality of life and patient preference measures for cancer patients and survivors

Last updated: 16.7.2025
Grant

The HORIZON-MISS-2021-CANCER-02-02 call, part of the Horizon Europe Mission on Cancer, focuses on improving the quality of life for cancer patients and survivors. This initiative seeks to develop and validate new measurement tools and approaches to better understand patient needs and preferences, thereby guiding health, social care, and employment policies. It stands out by integrating patient perspectives and multidisciplinary research to deliver impactful, patient-centered solutions.

Who is Funded and Program Objectives

This section outlines the eligibility criteria for applicants, the geographical scope of the program, and its overarching objectives. It details who can apply, where projects must be implemented, and what the program aims to achieve for cancer patients and survivors.

What Research is Funded

This section details the types of projects and thematic areas eligible for funding, focusing on how research and innovation actions can contribute to improving outcomes for cancer patients. It covers the specific sectors involved and the developmental stages of projects supported.

Type and Scope of Financial Support

This section outlines the financial aspects of the funding program, including the type of financial support offered and the overall budget allocated to this specific call.

Conditions and Program Requirements

This section details the key conditions and requirements that applicants and beneficiaries must adhere to, covering aspects from application procedures to collaboration expectations and data sharing.

Application Procedure Overview

This section guides potential applicants through the application submission and evaluation process for the funding program.

This section identifies the foundational legal and official documents that authorize and govern the HORIZON-MISS-2021-CANCER-02-02 funding program, ensuring transparency and adherence to established European Union frameworks.

Similar Programs

#cancer patient quality of life#patient preference measures#Horizon Europe Mission Cancer#cancer survivors#health outcomes#patient-reported outcomes#EU health funding#cancer research innovation#quality of life metrics#patient-centered care#social care cancer#eHealth cancer#public health policies#return to work cancer#multidisciplinary research teams#social innovation health#societal engagement research

Funding Overview

Funding Status

Funding Status:

Closed

Allocated Budget

Allocated Budget:

11.000.000 €

Deadline

Deadline:

26.04.2022

Open Until

Open Until:

31.12.2027

Award Channel

Award Channel:

Framework Programme Call

Region

Region:

EU-27 and Associated countries

Sectors

Sectors:

Healthcare, Research and Development, Service Sector, Social Enterprises, Information and Communication Technology, Pharmaceutical Industry

Beneficiaries

Beneficiaries:

Cancer patients, survivors, caregivers, health care professionals, supportive workers, counsellors, industry, regulators, institutions, health policy makers, labour market and social protection policy makers

Application Type

Application Type:

Consortium Required

Funding Stages

Funding Stages:

Applied Research, Experimental Development, Pilot Testing, Policy Development, Implementation

Funding Provider

Program Level:

European Union

Funding Body:

European Commission

Managed By:

Unknown

Additional Partners:

OMICS DATA SOLUTIONS LIMITED, Flow Analysis and Simulation Team, Samsun Provincial Health Directorate, AGECARE (CYPRUS) LTD, MINDS & SPARKS GMBH, EDEN TECH, INSTYTUT MEDYCYNY PRACY IMIENIA PROF. DRA MED. JERZEGO NOFERA W LODZI, TECH2MARKET SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA, SOCIETA PER L'ASSISTENZA AL MALATO ONCOLOGICO TERMINALE ONLUS, AITOWN S.R.L., Cancer Center Sp. z o.o., RISC SOFTWARE GMBH, ELVESYS, HABITUS ARASTIRMA VE DANISMANLIK LIMITED SIRKETI, Digestive Cancers Europe, NANTES UNIVERSITE, SPEMD - EVENTOS CIENTÍFICOS E CULTURAIS, UNIPESSOAL LDA, AZIENDA OSPEDALIERA SS.ANTONIO E BIAGIO E C. ARRIGO, PAGKYPRIOS SYNDESMOS KARKINOPATHON KAI FILON 1986, ACADEMISCH ZIEKENHUIS GRONINGEN, BCN HEALTH ECONOMICS & OUTCOMES RESEARCH S.L., SYNYO GmbH, Faculté de Médecine de Sfax, LASER CONSULT MUSZAKI-TUDOMANYOS ES GAZDASAGI TANACSADO KORLATOLT FELELOSSEGU TARSASAG, MOLI DE LES TINALLES SL, IDRYMA ERGODOTISIS EKPEDEFSIS NEOLEAS (IEEN), HOSPICES CIVILS DE LYON, WEBLYZARD TECHNOLOGY GMBH, Hybrid Core BV, CENTRO INTERNAZIONALE PER LA PROMOZIONE DELL'EDUCAZIONE E LO SVILUPPO ASSOCIAZIONE, S.A.M.O.T. Ragusa Onlus, Christos KONTOGIORGIS, Bukovinian State Medical University, GRANT GARANT SRO, SENSEDAT S.R.L., MEDICOFARMA BIOTECH SPOLKA AKCYJNA, Red Hospitalaria Recoletas, FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA, GOLEM - GESELLSCHAFT FUR INTEGRIERTE MIKROELEKTRONISCHE KOMPLETTLOESUNGEN GMBH, MENARINI SILICON BIOSYSTEMS SPA, CONCEPTTO DESARROLLO ESTRATÉGICO, SL, ARTIFICIAL INTELLIGENCE EXPERT SRL, KERALTY SAS, CONSULTECH TECHNOLOGIEBERATUNG GMBH, FACULDADE DE MEDICINA DENTÁRIA DA UNIVERSIDADE DE LISBOA, INSTYTUT GENETYKI CZLOWIEKA POLSKIEJ AKADEMII NAUK, wissenschaftliche-beratung, MOSAIQUES DIAGNOSTICS GMBH, EVENOR TECH SL, Grupo Colabora Formación y Proyectos, SL, GC GENOMICS ESPAÑA, SL, C.I.P. CITIZENS IN POWER, Progether AS, Cephalgo, GC GENOMICS GMBH, ROYAL COLLEGE OF SURGEONS IN IRELAND, SHINE 2EUROPE LDA

0 x 0
XS